OBJECTIVES: Several GLP-1 receptor agonists are available as weekly injections for treatment of type 2 diabetes.   These medications vary in their injection delivery systems, and these differences could impact quality of life and patient preference.  The purpose of this study was to estimate utilities associated with injection delivery systems for weekly GLP-1 therapies. METHODS: Participants diagnosed with type 2 diabetes in the UK (Inverness, Portree, Edinburgh, London) valued health states in time trade-off (TTO) interviews.  The health states (drafted based on literature, device instructions for use, and clinician interviews) had identical descriptions of type 2 diabetes, but differed in description of the treatment process.  One health state described an oral only treatment regimen (i.e., tablets), while six health states described oral treatment plus a weekly injection.  The injection health states differed in the treatment administration process (e.g., requirements for reconstituting the medication, waiting during medication preparation, and needle handling). RESULTS: A total of 209 participants completed interviews (57.4% male; mean age = 60.4y; 150 patients from Scotland and 59 from London).  The mean (SD) utility of the oral treatment health state was 0.89 (0.12), and all injection health states had significantly (all p < 0.01) lower utilities ranging from 0.86 (reconstitution, waiting, and handling) to 0.88 (weekly injection without any of the three treatment administration requirements).  Utility differences among the injection health states suggest that each administration requirement had a small but measureable disutility (i.e., negative utility difference).  Disutility values include -0.004 (reconstitution), -0.004 (needle handling), -0.010 (reconstitution, needle handling), and -0.020 (reconstitution, waiting, needle handling). CONCLUSIONS: Findings suggest that the TTO method may be used to quantify preferences among different injection treatment processes.  It may be useful to incorporate these differences into cost-utility models comparing among weekly injectable treatment for patients with type 2 diabetes.